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evaluate whether the pricing and reimbursement decision of new drugs in Taiwan’s 
NHI to fulﬁll the transparency and the expectation of public beneﬁts.
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OBJECTIVES: Clinical trial data are typically published in journals with a therapeutic 
area focus and accessed by researchers and health care providers (HCPs) for the 
purposes of sharing knowledge and improving outcomes for patients. Pharmacoeco-
nomic and health outcomes data are published for the same reasons, but often are 
most relevant to payers and other managed care decision makers. Yet there is limited 
knowledge of what factors make health outcomes publications most valuable to payers 
and HCPs and of how health outcomes decisions are inﬂuenced by publications. Our 
goal was to assess the impact of health outcome-related publications using literature 
citation data from two major web search engines that index scholarly literature. We 
envision that enhanced understanding of how health outcomes publications are sub-
sequently used may improve the quality of future publications and maximize useful-
ness to health care providers, payers, and patients. METHODS: In order to determine 
which types of papers were most read or most used to inform subsequent studies, we 
identiﬁed a sample of health outcomes papers published within the past 5 years and 
used Google Scholar and SciSearch to collect data on the number of times these 
publications were cited in subsequent research papers. RESULTS: Number of citations 
ranged from 0–57 per publication. Average number of citations was 10.2 per publica-
tion. Articles in therapeutically focused journals as well as cross-therapeutic health 
outcomes focused journals were frequently cited. CONCLUSIONS: These ﬁndings 
contribute to a growing understanding of the value of health outcomes publications 
for payers, health care decision-makers, and researchers in academia, government, and 
industry.
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OBJECTIVES: To assess the impact of recent pharmaceutical reform in South Korea 
METHODS: Descriptive analysis RESULTS: The South Korean National Health 
Insurance (NHI) system recently introduced a reform in pharmaceutical reimburse-
ment, with the purpose of increasing rational resource use in drug spending. The new 
policy aims to take the cost-effectiveness and budget impact of newly introduced drugs 
into account in payment decisions, and to re-evaluate the economic rationale of for-
merly existing drugs in the NHI drug reimbursement list. Under the new policy, a new 
drug goes through two stages; the ﬁrst stage of reimbursement decision, and the second 
stage of price negotiation. That is, once a drug is determined to be in the reimburse-
ment list, then it will go through a price negotiation process. Recent data reveal that 
the new policy, called the PLSP(positive list system policy), somewhat reduced the rate 
of reimbursement listing and successful price negotiations. The impact of PLSP would 
be diverse, including economic effects, access to new drugs, and dynamic efﬁciency. 
It is also true that the new policy faces challenges and confronts a number of issues, 
such as availability of data, utility measurement, threshold, modeling, degree of evi-
dence use, and decision-making process. CONCLUSIONS: This paper will provide a 
review of the ﬁrst three years policy outcomes, and attempt to assss the Korean PLSP 
in terms of the challenges and issues mentioned above.
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OBJECTIVES: Health care providers across the globe are facing the signiﬁcant ﬁnan-
cial challenge of funding new, innovative and expensive medicines for populations 
who are living longer and demanding better care. This funding dynamic has not only 
increased immediate ﬁnancial pressures on health care systems but also raises the level 
of risk associated with uncertainty around both clinical efﬁcacy and budgetary impact. 
To address this, payers are raising market access hurdles and implementing new cost 
containment measures. In response, industry is developing new pricing and reimburse-
ment strategies. Risk sharing is one example of how payers are trying to ensure value 
for money. This study assesses whether risk-sharing agreements have the necessary 
components to become sustainable in the coming years. METHODS: Secondary 
research was conducted to categorize and assess the types of risk-sharing agreements 
currently in place. Primary research was then used to obtain both payer and industry 
insight about the success and shortcomings of risk sharing and to anticipate how 
risk-sharing agreements are likely to evolve in the future. RESULTS: Risk sharing is 
often a misnomer. While some risk sharing agreements are developed to address 
uncertainty around clinical evidence, the majority of them focus on reducing the 
ﬁnancial impact of new products independent of the clinical beneﬁt. CONCLUSIONS: 
This analysis suggests that there is no one perfect method of risk sharing. In order for 
risk sharing to transition from a trend into a sustainable method of ﬁnancing new 
therapies, a careful understanding of the risk a new therapy poses and how to best 
mitigate that risk is needed.
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OBJECTIVES: A common goal among biopharmaceutical product development 
teams is incorporating market access considerations, e.g., clinical trial and outcomes 
data, health technology assessment (HTA) organization requirements, and pricing 
scenarios earlier in commercial planning in order to properly align product value with 
payer motivations. This research investigates the utility of a framework for commer-
cial teams to assess therapeutic category and product access opportunities; and to do 
so simultaneously in heterogeneous market access environments. The resulting graphi-
cal framework can be used by pharmaceutical ﬁrms to evaluate product positioning 
relative to various market access scenarios in order to inform product development 
and resource investment decisions. METHODS: A simpliﬁed payer value equation 
[(efﬁcacy + safety + burden of disease)/(product price—cost offsets)], is used to 
develop a graph to assess therapeutic areas and products relative to market access 
thresholds. Products are plotted using product value (y-axis) and a combination of 
disease burden and unmet medical need (x-axis). Market access thresholds are plotted 
as curves which represent the level of product innovation required to achieve various 
levels of market access. Movement across thresholds depicts signiﬁcant change in that 
product’s market access (e.g., non-reimbursed versus reimbursed). The position of 
market access thresholds can be estimated by deﬁning market access to existing 
products within individual payer systems. Analyzing product positioning simultane-
ously in multiple markets can be achieved by overlaying such graphs and aligning 
them along similar market access thresholds. RESULTS: This framework can be used 
to illuminate the level of product innovation required to meet the increasingly strin-
gent requirements for market access and inform ﬁrms’ investment decisions. CON-
CLUSIONS: Market access environments are complex and dynamic. Assessing 
therapeutic category and the attributes of new medicines relative to market access 
thresholds can inform pharmaceutical ﬁrms’ strategies to generate evidence of product 
value that are aligned with payer priorities.
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OBJECTIVES: To look into the impact of the drug policies in the Slovak Republic in 
2006–2009. To evaluate drug policy in terms of drugs’ accessibility, extent of patients’ 
co-payments and introduction of innovative drugs. To compare market developments 
in Slovakia to its neighbors, and EU/OECD countries. METHODS: We calculated the 
impact of several regulatory measures on the size of the market and health insurance 
expenditure: a) Lowering the VAT for drugs from 19% to 10% b) ﬂat price cut (−6.6% 
and −7.4%) c) introduction of degressive mark-up for wholesalers and for pharmacies 
d) two rounds of the international reference pricing.The data on drugs consumption 
were from national databases IMS Health and Pharmadata Ltd. We paired these data 
with reimbursement lists published by Slovak Ministry of Health. We compared trends 
in the Slovak drug market to market trends in neighboring countries and to OECD/
EU markets. RESULTS: In 2006 through 2009, the actual calculated savings on 
publicly-covered drugs reached EUR 160 mil due to the ﬂat price cuts, 385 mil due 
to two international reference pricing rounds and EUR 40 mil due to the degressive 
mark-up. The total volume of the Slovak market in 2009 was 31080 mil in manufac-
turers’ prices, in a country of 5,4 mil inhabitants. Consumption of drugs per capita 
reached app. 3200. CONCLUSIONS: Slovak drug policy was able to signiﬁcantly 
decrese the share of pharma expenditure in total health expenditure while increasing 
access new to drugs. Annual growth of the market in the period averaged 6.3% (1.4% 
in 2009), share of drugs in total health expenditure fell from 37% to 27%%, more 
than 100 new molecules s entered the market, and co-payments are astable app. 12% 
of total drug expenditure. We noticed this trend of decreasing market growth also in 
west European countries, but in middle-east European countries the growth of drug 
market was increasing by more than 10% also in 2009.
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OBJECTIVES: The objective of this study is to empirically investigate how the medical 
loss ratio (MLR) changes over time and what factors contribute to that change for 
patients enrolled to Medicare Advantage Special Need Plans. METHODS: We used a 
data supplied by a Medicare Advantage Special Need Plan, which include enrollees’ 
monthly premiums and expenses. The data also provide enrollees’ demographic infor-
mation and CMS risk scores and information regarding facilities and providers par-
ticipating in this plan. We deﬁned MLR as the total amount of revenues from health 
insurance premiums that is spent to pay for the medical services covered by the plan. 
Next, we created a panel data structure and deployed multilevel econometric models 
in our analysis. Finally, we used Hausman test to evaluate the signiﬁcance of ﬁxed-
effect estimators versus the alternative random-effect estimators. RESULTS: We found 
